01/08/2026
Nature published new U.S. peer-reviewed data validating the Prostatype® P-score for prostate cancer risk stratification at diagnosis. In a multiethnic VA cohort, Prostatype predicted prostate cancer–specific mortality with a c-index of 0.87, outperforming PSA, grade, and NCCN risk group, with robust performance in intermediate-risk patients. Over 70% African American, addressing a major validation gap.
Across prior validations, the Prostatype P-score has also shown:
• 10-year metastasis prediction with AUCs in the ~0.88 range
• Adverse pathology prediction at prostatectomy with AUCs ~0.81
• Consistent performance across demographically diverse populations in 5 countries and 3 continents.
• Long term prediction with 25-year data presented at AUA 2024 demonstrating the Prostatype® P-score stratified biochemical recurrence and prostate cancer–specific mortality—with no prostate cancer deaths in the low- or intermediate-risk groups supporting superior biologic risk stratification.
Collectively, these data support Prostatype as a clinically meaningful genomic classifier to help reduce both undertreatment of aggressive disease and overtreatment of indolent prostate cancer at the point of diagnosis.
The Prostatype® Test evaluates expression levels of three stem cell genes (IGFBP3, F3, and VGLL3), which are combined with PSA, stage, and grade to calculate P-score. Previous research found P-score accurately predicts prostate cancer (PC) specific mortality (PCSM) in patients with newly diagnosed ...
